Isotretinoin maintenance therapy for glioblastoma: A retrospective review *

Abstract

Objectives

The current standard treatment of glioblastoma includes maximal safe surgical resection, radiation, and temozolomide. Although isotretinoin has been used for maintenance therapy to delay tumor recurrence, this approach has not been proven to be effective. The objectives of the study are to compare the overall survival, progression-free survival and tolerability of isotretinoin maintenance therapy in patients who received isotretinoin maintenance therapy to patients who did not receive this treatment.

Methods

This study is a retrospective review of adult patients with glioblastoma treated at MD Anderson Cancer Center from 2004 to 2009. Patients who underwent surgical resection, radiation with concurrent temozolomide, and adjuvant treatment with temozolomide were included in the control group, and compared to similarly treated patients who received isotretinoin maintenance following adjuvant temozolomide.

Results

Eighteen patients who received isotretinoin maintenance therapy and 70 control patients were included in the analysis. Progression-free survival was 25.3 months with maintenance therapy versus 8.3 months for those not receiving maintenance (p = 0.04). There was no difference in the 2-year or 3-year overall survival estimates (p = 0.11). The common toxicities of isotretinoin included dermatologic-, metabolic-, and psychiatric-related adverse effects.

Conclusions

Isotretinoin maintenance therapy was associated with increased progression-free survival, but did not increase the overall survival in this retrospective review. The potential benefit of maintenance therapy should be weighed against toxicities and negative impact on quality of life in this patient population.

Keywords

Glioblastoma isotretinoin maintenance therapy

Get full access to this article

View all access options for this article.

References

Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2010. National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/ (2010, accessed 20 September 2010).

Central nervous system cancers. V.1.2012. NCCN clinical practice guidelines in oncology, 2012.

Stupp

Mason

van den Bent

. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996.

Reboul

George

Louisot

. Study of retinoic acid effect upon retinoic acid receptors beta (RAR-beta) in C6 cultured glioma cells. Biochem Mol Biol Int 1995; 36: 1097–1105.

Bouterfa

Picht

Kess

. Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery 2000; 46: 419–430.

Wismeth

Hau

Fabel

. Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy – a phase II study. J Neuro Oncol 2004; 68: 79–86.

Yung

Kyritsis

Gleason

. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 1996; 2: 1931–1935.

Phuphanich

Scott

Fischbach

. All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol 1997; 34: 193–200.

Jaeckle

Hess

Yung

. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2003; 12: 2305–2311.

10.

Butowski

Prados

Lamborn

. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 2005; 5: 1454–1459.

11.

See

Levin

Yung

. 13-cis-retinoic acid in the treatment of recurrent glioblastoma mulitforme. Neuro Oncol 2004; 6: 253–258.

12.

Clarke

Iwamoto

Sul

. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009; 23: 3861–3867.